Geleris (2020)
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
10.1056/NEJMoa2012410
https://www.nejm.org/doi/full/10.1056/NEJMoa2012410
Treatment
Treatment for COVID-19 (Treated with hydroxychloroquine vs. Not received)
COVID-19 (severe/fatal)
Hazard ratio: 2.370 (1.840-3.020) Univariate analysis

United States of America

Prospective observational study

Medical records

1376

consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation to the emergency department

Of the 1376 patients, 811 (58.9%) received hydroxychloroquine (median duration of treatment, 5 days) and 565 (41.1%) did not.

Median

23 Day


COVID-19 (severe/fatal)

346

The primary end point was a composite of intubation or death in a time-to-event analysis. Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation).


Treatment

Treatment for COVID-19

hydroxychloroquine treatment

Not received

Treated with hydroxychloroquine


Hazard ratio

2.370 (1.840-3.020)

No

Yes

No

crude analysis


none

Good

No